entertainment -WSS

entertainment

author：hotspot 2025-10-01 18:45:14 - browse：45

Fatty liver foregrounds arteries and veins surrounded by red blood cells — health coverage from STAT — Adobe

As drugmakers race to join the obesity drug market ignited by the approval of Wegovy and Zepbound, they’re not just competing on their drugs’ weight loss effects. They’re also competing on their products’ ability to treat a severe form of liver disease.

A new update of the STAT Obesity Drug Tracker shows that at least 23 — about one-fifth — of the 105 obesity treatments in development or on the market are also being investigated for metabolic dysfunction-associated steatohepatitis, the fatty liver disease known as MASH (and previously called NASH).

In this update, STAT has added a category — “other diseases investigated” — to show conditions beyond obesity for which a compound is being studied. Type 2 diabetes is the most common – it’s long been linked to obesity, and the latest GLP-1 treatments like Wegovy and Zepbound were initially developed as diabetes drugs. But behind diabetes, the next most common disease under investigation for obesity candidates is MASH.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： Doudna institute plans to 'cure hundreds of diseases' with CRISPR

focus

WSS

New menopause drug shows promise in relief for hot flashes

UnitedHealth wins $3.3 billion takeover of Amedisys

Readout LOUD podcast: 2023 in review, and a look at biotech in 2024

DeSantis can now import cheaper drugs. But will Biden get credit?

Lilly’s obesity pill cuts 15% of weight at highest dose in mid

New England Journal of Medicine addresses racist history, slavery

focus

entertainment

explore

Medical records are filled with copy

ADA: All diabetes patients should be screened for liver condition

State Dept. review finds Biden bears some blame for Afghanistan failures

Lilly’s obesity pill cuts 15% of weight at highest dose in mid

In age of alternative facts, a scholarly course on calling out crap

Synthetic human embryos? Researchers say term is overblown

Affirmative action in medical school literally saved lives

Health and fitness trackers are measuring the wrong things

Hepatitis C has a cure — but many Americans still lack access to it

Lilly’s obesity pill cuts 15% of weight at highest dose in mid

knowledge

What Wagner Group's armed rebellion could mean for Russia's endgame in Ukraine

How I ended up pumping milk in a bathroom stall at JPM 2024

New menopause drug shows promise in relief for hot flashes

JPM 2024: FogPharma’s CEO unveils ‘contrarian’ plan in oncology

Why do we get seasonal allergies?

Heart disease and mental health: A look at cardiac psychology

focus

focus

focus

knowledge